tweetindex
RU

OncLive.com ✓

@OncLive · New Jersey, USA · joined 28 May 2009

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

50 275Followers
2 005Following
120 057Posts total
6.6KViews on collected posts

Последние посты

🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology Dive into the efficacy and safety highlights: https://t 66 views · 0 likes · 0 reposts · 0 replies Open on X →
🩸Excited for @SocietyofHemOnc 2026? We've got you covered with expert insights on all the most important things to watch for going into the meeting. Full details 📈: https://t.co/UjtkEpaSWM #leusm #lymsm #mmsm #mpnsm #oncology @AaronGerds @LymphClinician @RaajitRampal https://t 117 views · 0 likes · 0 reposts · 0 replies Open on X →
Register now to attend the launch broadcast for JIDEYTRO™ (zidesamtinib), hosted by Dr. Mark Socinski, MD. Learn about trial data, efficacy outcomes, and safety profile of JIDEYTRO (zidesamtinib). Click here to sign-up: https://t.co/HDV2XI8Qku https://t.co/s4f8wWaORy 120 views · 1 likes · 0 reposts · 0 replies Open on X →
📰 GLP-1s are generating significant buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression. #bcsm #oncology Read insights from Deena Graham, MD, of @JTCancerCenter and @HMHNewJersey here: https://t.co/a2g84CZeJ0 597 views · 5 likes · 1 reposts · 0 replies Open on X →
@OncLive https://t.co/bn7LjH2bl9 64 views · 0 likes · 0 reposts · 0 replies Open on X →
@statnews Pkg insert/label for Rasonque https://t.co/ZDsZNaeBnL 2.7K views · 0 likes · 0 reposts · 0 replies Open on X →
🚨BREAKING: The news the pancreatic cancer field has been awaiting is here. The @FDA has approved daraxonrasib for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent h 2.9K views · 19 likes · 6 reposts · 1 replies Open on X →

На фоне аккаунтов своего размера

7 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. ниже своих по обоим показателям — и по охвату, и по отклику.

Медианные просмотры120этот аккаунт924медиана для 10K–100K
Охват, %0.24%этот аккаунт3.62%медиана для 10K–100K
Вовлечённость, %0.04%этот аккаунт1.52%медиана для 10K–100K
ПоказательЭтот аккаунтМедиана для 10K–100KОтношение
Медианные просмотры на пост1209240.13×
Охват (просмотры ÷ подписчики)0.24%3.62%0.07×
Вовлечённость0.04%1.52%0.02×

Другие в этом диапазоне →   Сравнить с другим аккаунтом →   Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.9K26 Aug
2.7K
64
5973 Sep
120
117
66

Last 7 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.95%26 Aug
0.04%
0.00%
1.01%3 Sep
0.83%
0.00%
0.00%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes69.4%25 in total
Reposts19.4%7 in total
Replies2.8%1 in total
Quotes8.3%3 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Похожие аккаунты